Navigation Links
Actinium Pharmaceuticals, Inc. Receives $3.5m from Exercise of Warrants
Date:6/7/2013

NEW YORK, June 7,­­­­ 2013 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (OTCQB: ATNM) announced today the recent issuance of 2,095,204 of its shares of common stock pursuant to the exercise of A-Warrants originally issued in connection with a private placement that closed in January 2013.  The warrants were exercised at US$ 1.65 per share, resulting in gross proceeds of US$ 3,457,087 for the Company.  As of June 7, 2013 the total number of outstanding common stock is 15,825,394 shares.

"The proceeds from these exercised warrants will be used for the Companies clinical and preclinical programs and for general working capital," said Sergio Traversa, Interim Chief Executive Officer of Actinium Pharmaceuticals.  "This capital will allow us to continue to develop our drug candidates for treatment of the most difficult forms of cancer, including Acute Myeloid Leukemia, where they have made significant advances and already helped a number of patients," added Dragan Cicic, MD, Chief Medical Officer of Actinium Pharmaceuticals.  "The Company intends to advance its programs into late phases of clinical trials and add new programs by the end of 2013."

Shareholders exercised 2,095,204 (67.2%) of the 3,118,988 originally issued A-warrants. 

About Actinium Pharmaceuticals

Actinium Pharmaceuticals, Inc., based in New York, NY, is a biopharmaceutical company that develops innovative alpha particle immunotherapeutics based on its proprietary platform for the therapeutic utilization of alpha particle emitting actinium-225 and bismuth-213 radiopharmaceuticals in association with monoclonal antibodies.

For more information:

Visit our web site www.actiniumpharmaceuticals.com or

Contact:
'/>"/>

SOURCE Actinium Pharmaceuticals Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Actinium Pharmaceuticals Clinical Results to be Presented at 8th International Symposium on Targeted Alpha Therapy Conference
2. Actinium Pharmaceuticals, Inc. Receives Notice of Patent Allowance for a Key Application
3. Cactus Ventures, Inc. Changes Name to Actinium Pharmaceuticals, Inc.
4. Actinium Pharmaceuticals, Inc. To Present at the 15th Annual BIO CEO Investor Conference
5. Actinium Pharmaceuticals to Present at EMIT Targeted Radiotherapy Conference
6. University of Pennsylvania joins Actinium Pharmaceuticals Multicenter Actimab-A Trial
7. Additional Clinical Data from Two Trials on Actinium Pharmaceuticals Iomab-B to be Presented at American Society of Hematology (ASH) Annual Meeting
8. Actinium Pharmaceuticals Sponsors Webinar on Clinical Use of Alpha Immunotherapy
9. Actinium Pharmaceuticals Announces New Round of Financing
10. Gerri Henwood Joins Actinium Pharmaceuticals as Chief Development Officer
11. Actinium Pharmaceuticals Commences Screening for the Second Cohort of Patients in the Companys Ongoing Phase I/II Trial in Acute Myeloid Leukemia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/20/2014)... 20, 2014  The National Association of Drug ... achieved by the real-time, pseudoephedrine (PSE) blocking system ... Log Exchange (NPLEx), automatically blocks unlawful PSE sales ... offenders and make arrests. Data released by NPLEx ... blocked the sale of more than 32,105 ...
(Date:8/20/2014)... , Aug. 20, 2014  The National Association ... latest results achieved by the real-time, pseudoephedrine (PSE) ... National Precursor Log Exchange (NPLEx), automatically blocks unlawful ... down methamphetamine offenders and make arrests. Data released ... Missouri blocked the sale of more ...
(Date:8/20/2014)... Aug. 20, 2014 Reportlinker.com ... report is available in its catalogue: ... Infection Control (Sterilization, Disinfection, Testing and ... Given the cost ... demand has increased for solutions that ...
Breaking Medicine Technology:Indiana's Stop-Sale System Achieves Significant Results In Battle Against Meth 2Missouri's Stop-Sale System Achieves Significant Results In Battle Against Meth 2The Market for Hospital-Acquired Infection Control (Sterilization, Disinfection, Testing and Treatment) 2The Market for Hospital-Acquired Infection Control (Sterilization, Disinfection, Testing and Treatment) 3The Market for Hospital-Acquired Infection Control (Sterilization, Disinfection, Testing and Treatment) 4The Market for Hospital-Acquired Infection Control (Sterilization, Disinfection, Testing and Treatment) 5The Market for Hospital-Acquired Infection Control (Sterilization, Disinfection, Testing and Treatment) 6
... Cetrorelix showed good safety and tolerability profile ... level,Japanese partner Shionogi initiates Phase 2b trial, ... AEterna,Zentaris Inc. along with its Japanese partner ... for a Phase 2a trial with,cetrorelix in ...
... WIRE)--Mar 22, 2007 - Nutra Pharma,Corp. (OTCBB: ... for HIV and Multiple Sclerosis has today ... received notification of,acceptance of its paper for ... conference issue., The article, entitled "Alpha-Cobratoxin as ...
Cached Medicine Technology:AEterna Zentaris Reports Positive Results with Cetrorelix in BPH,for Japanese Phase 2a Trial 2AEterna Zentaris Reports Positive Results with Cetrorelix in BPH,for Japanese Phase 2a Trial 3AEterna Zentaris Reports Positive Results with Cetrorelix in BPH,for Japanese Phase 2a Trial 4Nutra Pharma Announces Publication of Research on Treatment for,Multiple Sclerosis 2Nutra Pharma Announces Publication of Research on Treatment for,Multiple Sclerosis 3
(Date:8/21/2014)... (PRWEB) August 21, 2014 Taking its ... all aspects of life, St. Louis’ Sound Mind Café ... better and revolutionized its online presence. Reorganized to highlight ... the new website makes navigating for information and scheduling ... an easily accessible menu-bar in jet black, the cafe’s ...
(Date:8/21/2014)... 2014 According to a recent study ... environmental factors may outweigh genetics in the development and severity ... the world’s population is nearsighted, and this study provides valuable ... is an important finding in the field of ophthalmology,” says ... we finding better ways to treat ophthalmological conditions , ...
(Date:8/21/2014)... While golfing in Scotland and abroad, Biteback ... focused on his game due to the incessant buzzing ... and continual need to spray insect repellent became so ... from insects while golfing. He ultimately found a solution ... Banking Industry, decided to change direction and launch Biteback ...
(Date:8/21/2014)... Denver marketing agency Webolutions® has ... Lung Association in Colorado’s 2014 Run the ‘Rocks ... a sponsor,” said Curt Huber, Chief Development Officer, American ... Lung Association in Colorado, “and we’re eager to see ... they’ve defined.” , Webolutions has also created and is ...
(Date:8/21/2014)... August 21, 2014 HIPAA Secure Now! ... making it possible for EHR vendors to now offer ... requirement for achieving meaningful use. , HIPAA Secure ... to medical practices throughout the U.S. The company assesses ... information (ePHI) from each system and device used by ...
Breaking Medicine News(10 mins):Health News:Sound Mind Cafe Launches Revamped Website and Hires Hypnotist to Team 2Health News:Study Suggests Environmental Factors May Outweigh Genetics When It Comes to Myopia 2Health News:Financial VP Fights Pesky Bugs with Launch of Biteback Sports Insect Shield® Golf Apparel 2Health News:Denver Marketing Agency Webolutions Named Inspirational Sponsor for 2014 Run the ‘Rocks 5K 2Health News:Denver Marketing Agency Webolutions Named Inspirational Sponsor for 2014 Run the ‘Rocks 5K 3Health News:HIPAA Secure Now! Ramps up EHR Partner Program, Helps Healthcare Providers Achieve Meaningful Use under Revised CMS Deadlines 2
... September 15, 2008 In a retrospective analysis of ... older, osteoporosis fractures resulted in fracture-related medical expenses of ... presented at the American Society for Bone and Mineral ... analyze the actual long-term fracture-related medical expenses incurred over ...
... more effective than an older conventional antipsychotic in treating ... metabolic side effects, according to a new study funded ... Mental Health (NIMH). The study was published online ahead ... Journal of Psychiatry . , "Schizophrenia and schizophrenia-related ...
... CREEK, Calif., Sept. 14 Longs Drug,Stores Corporation ... it had,received an unsolicited, non-binding expression of interest ... of $75.00 per share in cash,for all of ... and,negotiating a definitive agreement. Longs, Board of Directors ...
... first time, researchers have identified variations in a single ... affecting African-Americans. This work was conducted by researchers at ... investigators at the Johns Hopkins University. The findings are ... Genetics and will be published in the October ...
... 14 Washington State Nurses,Association (WSNA), representing more ... Center (UWMC), held a candlelight vigil to,demonstrate the ... negotiations. The last mediation session is scheduled on ... between Shifts - The Hospital,s proposal to reduce ...
... Understanding Harmful Bacteria Honored with Special Achievement ... ... 13 The 2008 Albert Lasker Medical,Research Awards ( http://www.laskerfoundation.org ) ... nation,s most,distinguished honor for outstanding basic and clinical medical research,discoveries and ...
Cached Medicine News:Health News:Retrospective study analyzes expenses of osteoporosis-related fracture over 3 years 2Health News:Newer antipsychotics no better than older drug in treating child and adolescent schizophrenia 2Health News:Longs Drug Stores Confirms Receipt of Expression of Interest from Walgreens 2Health News:Longs Drug Stores Confirms Receipt of Expression of Interest from Walgreens 3Health News:Newly found gene variants account for kidney diseases among African-Americans 2Health News:Newly found gene variants account for kidney diseases among African-Americans 3Health News:Newly found gene variants account for kidney diseases among African-Americans 4Health News:Registered Nurses at UW Medical Center Hold Candlelight Vigil to Highlight Concerns for Quality and Safe Patient Care 2Health News:Discoverers of Small Regulatory RNAs and Cholesterol-Lowering Drugs to Receive Lasker Awards for Medical Research 2Health News:Discoverers of Small Regulatory RNAs and Cholesterol-Lowering Drugs to Receive Lasker Awards for Medical Research 3Health News:Discoverers of Small Regulatory RNAs and Cholesterol-Lowering Drugs to Receive Lasker Awards for Medical Research 4
... A necessary addition ... set, the Reichert Trial ... fit and smooth controls ... fitting.,The robust design, high-quality ...
... Master is designed and constructed ... service and give the professional ... procedures. It embodies the characteristics ... most, including accuracy, speed, ease, ...
The Maverick Over-The-Wire balloon catheter delivers a new level of performance to meet the changing demands of interventional cardiology....
... Illumination is provided by a cool-running, ... light only what you need to see ... best of all they are maintenance free ... light bulb. Every Phoroptor comes with a ...
Medicine Products: